Abstract 527P
Background
Leptomeningeal metastases (LM) of lung cancer represent a severe neurological complication with a poor prognosis and limited effective treatments. Although intraventricular chemotherapy (IVC) is the preferred management for LM, there is currently insufficient data to support its effectiveness.
Methods
We conducted a retrospective study that analyzed data from consecutive patients with LM from lung adenocarcinoma who underwent Ommaya reservoir insertion at the Nanjing Chest Hospital between 2020 and 2022. The diagnosis of LM was based on either cerebrospinal fluid (CSF) cytology or concordant clinical and neuroimaging findings. The chemotherapy regimen consisted of pemetrexed (30mg or 50mg) and dexamethasone (5mg) administered twice a week for up to 2 weeks during the induction phase, followed by a maintenance phase once a month until progression or maximal doses were reached.
Results
We retrospectively analyzed 56 patients (median age, 56 years) with driver gene mutations, including 46 patients with EGFR mutations, 2 patients with other gene mutations, and 8 patients with non-driver genes. Of the patients, 48.3% had an ECOG PS of 4, 35.7% had an ECOG PS of 3, and 16% had an ECOG PS of 2. Additionally, 41 patients (73.2%) received a 30mg dose of pemetrexed, and 15 patients (26.8%) received a 50mg dose. In all patients, 31 had a response, 19 had stable disease (SD), and 6 had disease progression (PD), resulting in an overall response rate (ORR) of 55.4% and a disease control rate (DCR) of 89.3%. The median progression-free survival (mPFS) was 6.8 months, and the median overall survival (mOS) was not reached. Subgroup analysis showed that the mPFS for the pemetrexed 50mg and 30mg groups was 12 months and 6.8 months, respectively (p=0.006), and the mPFS was 9.6 months versus 4 months in the ECOG PS of 2-3 and 4 arms(Fig1B), respectively (p=0.001). The overall adverse event (AE) rate was 65%, with all adverse effects, including nausea, vomiting, seizures, and myelosuppression, being mild and transient.
Conclusions
In this real-world study, IVC with pemetrexed demonstrated excellent and encouraging results in patients with lung adenocarcinoma and LM, at an acceptable cost of toxicity.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
592P - Treatment patterns and outcomes in patients with advanced non-small cell lung cancer with MET exon 14 skipping alterations in China
Presenter: Hanxiao Chen
Session: Poster Display
Resources:
Abstract
593P - MET TKIs in Asian patients (pts) with MET exon 14 skipping NSCLC: A matching-adjusted indirect comparison (MAIC)
Presenter: E-e Ke
Session: Poster Display
Resources:
Abstract
594P - The treatment pattern and clinical outcome in NSCLC patients with MET alteration: A retrospective real-world analysis in China
Presenter: Yongfeng Yu
Session: Poster Display
Resources:
Abstract
595P - Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)
Presenter: Koichi Goto
Session: Poster Display
Resources:
Abstract
596P - Repotrectinib in patients (pts) from Asia and China with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC): Results from the phase I/II TRIDENT-1 trial
Presenter: Ross Soo
Session: Poster Display
Resources:
Abstract
597TiP - A phase I/II study to evaluate the safety and anti-tumor activity of JIN-A02 in patients with EGFR TKI-refractory, EGFR-mutant advanced NSCLC
Presenter: Sun Min Lim
Session: Poster Display
Resources:
Abstract
598TiP - Exploration of aumolertinib in first-line treatment for advanced non-small cell lung cancer patients of performance status 3 with EGFR mutations (19del and L858R)
Presenter: Haiyi Deng
Session: Poster Display
Resources:
Abstract
599TiP - A prospective study of savolitinib plus docetaxel in pretreated EGFR/ALK/ROS1/METex14m-wildtype advanced NSCLC patients with MET overexpression (FirstMET)
Presenter: Shuting Zhan
Session: Poster Display
Resources:
Abstract
600TiP - Phase III study of telisotuzumab vedotin (Teliso-V) vs docetaxel in pretreated c-Met overexpressing EGFR wildtype (WT) non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC)
Presenter: Junko Tanizaki
Session: Poster Display
Resources:
Abstract
601P - Pembrolizumab in patients of Chinese descent with microsatellite instability-high/mismatch repair deficient advanced solid tumors: KEYNOTE-158
Presenter: Xiaohua Wu
Session: Poster Display
Resources:
Abstract